Allena Pharmaceuticals, Inc. (ALNA) financial statements (2022 and earlier)

Company profile

Business Address ONE NEWTON EXECUTIVE PARK
NEWTON, MA 02462
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29,988 30,00761,64394,494
Cash and cash equivalents29,988 30,00761,64394,494
Other undisclosed current assets3,018 3,0282,8261,539
Total current assets:33,006 33,03564,46996,033
Noncurrent Assets
Operating lease, right-of-use asset455 549
Property, plant and equipment1,173 401514127
Other noncurrent assets123 12324689
Total noncurrent assets:1,751 1,073760216
TOTAL ASSETS:34,757 34,10865,22996,249
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,510 6,4185,7633,673
Accounts payable1,030 3,0482,1381,724
Accrued liabilities4,480 3,3703,6251,949
Debt9,852 4,490 3,870
Other undisclosed current liabilities317    
Total current liabilities:15,679 10,9085,7637,543
Noncurrent Liabilities
Long-term debt and lease obligation210 6,0029,9805,516
Long-term debt, excluding current maturities  5,9889,9805,516
Operating lease, liability210 14
Liabilities, other than long-term debt   30320
Other liabilities   30320
Other undisclosed noncurrent liabilities(210)    
Total noncurrent liabilities:210 6,00210,0105,836
Total liabilities:15,889 16,91015,77313,379
Stockholders' equity
Stockholders' equity attributable to parent18,868 17,19849,45682,870
Common stock83 252120
Additional paid in capital265,237 182,117167,040164,807
Accumulated deficit(246,452) (164,944)(117,605)(81,957)
Total stockholders' equity:18,868 17,19849,45682,870
TOTAL LIABILITIES AND EQUITY:34,757 34,10865,22996,249

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(47,649) (47,525)(35,593)(20,950)
Operating loss:(47,649) (47,525)(35,593)(20,950)
Nonoperating income (expense)(1,014) 186(55)(700)
Investment income, nonoperating(976) 270575(443)
Other nonoperating expense(38) (84)(13)(257)
Interest and debt expense   (617) 
Loss before gain (loss) on sale of properties:(48,663) (47,339)(36,265)(21,650)
Other undisclosed net income   617 
Net loss attributable to parent:(48,663) (47,339)(35,648)(21,650)
Preferred stock dividends and other adjustments    (58)
Net loss available to common stockholders, diluted:(48,663) (47,339)(35,648)(21,708)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(48,663) (47,339)(35,648)(21,650)
Comprehensive loss, net of tax, attributable to parent:(48,663) (47,339)(35,648)(21,650)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: